Proactive Investors - Run By Investors For Investors

Cellmid’s évolis Professional product range to be sold in Europe

The évolis® professional products can now be imported into EU countries and the UK following comprehensive safety and compliance reviews.
Cellmid’s évolis Professional product range to be sold in Europe
The evolis professional product range will be sold in the EU by Cellmid’s cosmetics retail partner

Cellmid Limited’s (ASX:CDY) évolis® Professional anti-ageing hair care products have been registered for sale in the European Union and the UK representing the final step in a comprehensive regulatory compliance assessment of the products before they could be freely sold in Europe.

Key treatment and efficacy claims have been retained on the product labels during the review process, which provides for strong market positioning as efficacious products derived from natural plant extracts.

Cellmid has already established a partnership with one of the largest cosmetics retailers in Europe and it is expected that e-commerce sales on the partner’s platform will begin in the first half of financial year 2020.

READ: Cellmid alopecia patent granted in Europe for evolis hair therapy

According to industry reports, 50% of the UK beauty consumers look for products made with natural ingredients and 24% of German consumers choose to buy natural products.

In a discerning market such as the EU, the évolis Professional products - based on plant extracts and with strong clinical evidence - are expected to be well positioned.


The évolis Professional product range of all 11 SKUs will be sold in EU member states by Cellmid’s cosmetics retailer partner.

Sales through the e-commerce platform of Cellmid’s retail partner are expected to begin in the first half of next year in the EU, a large, discerning cosmetics market with relatively high disposable income, similar to the US.

Consistent with the company’s strategic plan released to the market at the end of February, the EU product registration represents yet another important milestone in the company’s plans for the global expansion of the évolis® brand.


View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
May 09 2019
Here we take a look under the hood of Shield Therapeutics
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use